Cargando…
Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies
At an upfront price of $2.125 million, the one-time gene therapy onasemnogene abeparvovec for spinal muscular atrophy, a rare neuromuscular disorder that is usually fatal by 2 years of age if untreated, has been called the “most expensive drug ever.” This flawed characterization raises important met...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391299/ https://www.ncbi.nlm.nih.gov/pubmed/33908277 http://dx.doi.org/10.18553/jmcp.2021.27.5.674 |